Beta Bionics, Inc.
BBNXNASDAQHealthcareMedical - Devices
Previous close
$19.05
−$0.43 · -2.21%
BBNX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
77
Undervalued
Momentum
44
Neutral
Sentiment
47
Mixed
Risk resilience
17
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBeta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Sean T. Saint
- Listed since
- Jan 30, 2025
- Employees
- 422
Market position
Day range
Current $19.05
52-week range
Current $19.05
- Open
- $19.22
- Previous close
- $19.48
- Volume
- 496.6K
- 0.45× average
- Average volume
- 1.1M
- Average daily volume
- Market cap
- 857.05M USD
- Beta
- 3.11
- Market reference 1
- 50-day average
- $16.111
- +18.24% above average
- 200-day average
- $17.1169
- +11.29% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.21B USD
- P/E (TTM)
- -11.34×
- P/B (TTM)
- 3.31×
- P/S (TTM)
- 7.2×
- EV / EBITDA
- -17.22×
- Earnings yield
- -5.93%
- Free cash flow yield
- -4.55%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 58.31%
- Operating margin
- -69.75%
- Net margin
- -61.32%
- Return on equity
- -25.45%
- Return on assets
- -22.27%
- Return on invested capital
- -23.91%
Financial health
- Debt / equity
- 0.03×
- Current ratio
- 8.66×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 100.25M USD | 65.12M USD | 12M USD | 179K USD |
| Cost of goods sold | 44.71M USD | 29.24M USD | 5.69M USD | — |
| Gross profit | 55.54M USD | 35.89M USD | 6.31M USD | 179K USD |
| Research and development | 34.79M USD | 26.18M USD | 17.94M USD | 31.43M USD |
| Selling, general, and administrative | 92.43M USD | 54.96M USD | 24.22M USD | 33.5M USD |
| Operating expenses | 127.22M USD | 81.14M USD | 42.16M USD | 66.02M USD |
| Interest income | 10.93M USD | 3.91M USD | 1.78M USD | 196K USD |
| Interest expense | — | — | — | 14K USD |
| Depreciation and amortization | 2.88M USD | 1.15M USD | 1.23M USD | 1.35M USD |
| Operating income | −71.68M USD | −45.25M USD | −35.85M USD | −65.84M USD |
| Net income | −73.2M USD | −54.76M USD | −44.1M USD | −64.75M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -1.81
- FY2025
- Latest fiscal-year revenue
- 100.25M USD
- FY2025 · +53.94% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$21.00
10.24% upsideRating distribution
8 ratingsBBNX news
BBNX peers
ETFs holding BBNX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM20.38M0.03%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI16.33M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 Value ETFIWN7.32M0.05%14.66B USD0.24%$224.81+0.45%
Vanguard Extended Market ETFVXF6.03M0.01%93.7B USD0.05%$245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA3.8M0.02%23.1B USD0.03%$34.83+0.52%
iShares U.S. Medical Devices ETFIHI3.76M0.11%3.49B USD0.37%$56.17+1.30%
Vanguard Russell 2000 ETFVTWO2.93M0.02%17.4B USD0.06%$121.25+0.74%
State Street SPDR S&P Health Care Equipment ETFXHE2.41M1.37%176.38M USD0.35%$96.68+1.37%iShares Russell 2000 ETFIWM- Market value
- 20.38M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 16.33M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 Value ETFIWN- Market value
- 7.32M
- Weight
- 0.05%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Vanguard Extended Market ETFVXF- Market value
- 6.03M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 3.8M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
iShares U.S. Medical Devices ETFIHI- Market value
- 3.76M
- Weight
- 0.11%
- AUM
- 3.49B USD
- Expense ratio
- 0.37%
- Price / 1D
- $56.17+1.30%
Vanguard Russell 2000 ETFVTWO- Market value
- 2.93M
- Weight
- 0.02%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
State Street SPDR S&P Health Care Equipment ETFXHE- Market value
- 2.41M
- Weight
- 1.37%
- AUM
- 176.38M USD
- Expense ratio
- 0.35%
- Price / 1D
- $96.68+1.37%
Continue in GoAI
Research BBNXresearch.disclaimer